KEGG   DRUG: Tarlatamab
Entry
D12234                      Drug                                   
Name
Tarlatamab (USAN);
Tarlatamab (genetical recombination) (JAN);
Tarlatamab-dlle;
Imdelltra (TN)
Product
IMDELLTRA (AMG757) (Amgen)
Formula
C4664H7139N1259O1454S34
Exact mass
105136.3894
Mol weight
105201.43
Sequence
QVQLQESGPG LVKPSETLSL TCTVSGGSIS SYYWSWIRQP PGKCLEWIGY VYYSGTTNYN
PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCASIAV TGFYFDYWGQ GTLVTVSSGG
GGSGGGGSGG GGSEIVLTQS PGTLSLSPGE RVTLSCRASQ RVNNNYLAWY QQRPGQAPRL
LIYGASSRAT GIPDRFSGSG SGTDFTLTIS RLEPEDFAVY YCQQYDRSPL TFGCGTKLEI
KSGGGGSEVQ LVESGGGLVQ PGGSLKLSCA ASGFTFNKYA MNWVRQAPGK GLEWVARIRS
KYNNYATYYA DSVKDRFTIS RDDSKNTAYL QMNNLKTEDT AVYYCVRHGN FGNSYISYWA
YWGQGTLVTV SSGGGGSGGG GSGGGGSQTV VTQEPSLTVS PGGTVTLTCG SSTGAVTSGN
YPNWVQQKPG QAPRGLIGGT KFLAPGTPAR FSGSLLGGKA ALTLSGVQPE DEAEYYCVLW
YSNRWVFGGG TKLTVLGGGG DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PCEEQYGSTY RCVSVLTVLH QDWLNGKEYK
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
LSLSPGGGGS GGGGSGGGGS GGGGSGGGGS GGGGSDKTHT CPPCPAPELL GGPSVFLFPP
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPCEEQ YGSTYRCVSV
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC
SVMHEALHNH YTQKSLSLSP GK
(Disulfide bridge: 22-95, 44-234, 156-222, 269-345, 409-477, 506-761, 509-764, 541-601, 572-582, 647-705, 796-856, 827-837, 902-960)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01FX33
Product: D12234<JP/US>
Efficacy
Antineoplastic
  Disease
Small cell lung cancer [DS:H00013]
  Type
Bispecific antibody
Target
DLL3 [HSA:10683] [KO:K06051]
CD3E [HSA:916] [KO:K06451]
  Pathway
hsa04330  Notch signaling pathway
hsa04658  Th1 and Th2 cell differentiation
hsa05200  Pathways in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX33 Tarlatamab
      D12234  Tarlatamab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-CD3/DLL3 Antibodies
    Tarlatamab
     D12234  Tarlatamab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D12234  Tarlatamab (USAN); Tarlatamab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3E
     D12234  Tarlatamab (USAN) <JP/US>
 Not elsewhere classified
  Environmental information processing
   Notch signaling
    DLL3
     D12234  Tarlatamab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12234
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12234
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12234
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12234
Other DBs
CAS: 2307488-83-9
PubChem: 497620647
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system